JP2003081839A - Immunopotentiator including trehalose - Google Patents
Immunopotentiator including trehaloseInfo
- Publication number
- JP2003081839A JP2003081839A JP2001269859A JP2001269859A JP2003081839A JP 2003081839 A JP2003081839 A JP 2003081839A JP 2001269859 A JP2001269859 A JP 2001269859A JP 2001269859 A JP2001269859 A JP 2001269859A JP 2003081839 A JP2003081839 A JP 2003081839A
- Authority
- JP
- Japan
- Prior art keywords
- trehalose
- tumor
- active ingredient
- immunopotentiator
- immunostimulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】この発明は免疫賦活剤、とり
わけ、有効成分としてトレハロースを含んでなる免疫賦
活剤に関するものである。TECHNICAL FIELD The present invention relates to an immunostimulant, and more particularly to an immunostimulant containing trehalose as an active ingredient.
【０００２】[0002]
【従来の技術】従来から、種々の制癌剤が微生物や天然
植物から生産されていることが知られている。その内の
いくつかのものは、制癌剤として実用化されている。特
に、放線菌由来の制癌剤として、マイトマイシンＣ、ブ
レオマイシン、アドリアマイシン、ネオカルチノスタチ
ン等が、キノコからはクレスチン、レンチナンが、さら
に西洋イチイからタキソールが知られており、治療に応
用されている。さらに、核酸塩基合成阻害剤として、５
−FUが知られているが、これらのうち多くの制癌剤は、
骨髄抑制、胃腸障害、心機能障害や脱毛といった副作用
を伴い、癌の患者にとって大きな負担となっている。
又、多くの癌患者において免疫能が低下し、癌の進行の
促進が見られたり、各種細菌に対する抵抗性が減弱し、
重篤な感染症にかかりやすくなる。このような背景か
ら、近年、臨床サイドから癌の治療法として、クオリテ
ィー・オブ・ライフという概念が検討されるようにな
り、制癌剤の領域についても、より副作用の少ない、か
つ癌患者の免疫能を亢進して癌の治療を試みることがで
きる免疫賦活剤の利用が盛んになってきている。2. Description of the Related Art Conventionally, it is known that various anticancer agents are produced from microorganisms and natural plants. Some of them have been put to practical use as anticancer agents. In particular, mitomycin C, bleomycin, adriamycin, neocarzinostatin and the like are known as carcinostatic agents derived from actinomycetes, krestin and lentinan are known from mushrooms, and taxol is known from western yew and have been applied to therapy. Furthermore, as a nucleobase synthesis inhibitor, 5
-FU is known, but many of these carcinostatic agents
With side effects such as bone marrow suppression, gastrointestinal disorders, cardiac dysfunction and hair loss, it is a great burden for cancer patients.
Moreover, in many cancer patients, the immunocompetence is lowered, promotion of cancer progression is seen, resistance to various bacteria is diminished,
Susceptible to serious infections. Against this background, the concept of quality of life has recently been considered as a treatment method for cancer from the clinical side, and in the field of anti-cancer agents as well, there are fewer side effects and the immunopotency of cancer patients has been improved. The use of immunostimulants, which can be accelerated to try to treat cancer, is becoming popular.
【０００３】トレハロースは２分子のグルコースが還元
性基同士で結合してなる二糖類であり、自然界において
は細菌、真菌、藻類、昆虫、甲殻類などに広く分布して
いる。食品、化粧品及び医薬品の諸分野においては、蔗
糖に代わる糖質としてのトレハロースの需要が急速に伸
びつつあるが、腫瘍に対して予防又は治療効果があるこ
とは全く知られていない。Trehalose is a disaccharide in which two molecules of glucose are bound to each other by reducing groups, and is widely distributed in nature, such as bacteria, fungi, algae, insects and crustaceans. In various fields of foods, cosmetics, and pharmaceuticals, demand for trehalose as a sugar substitute for sucrose is rapidly increasing, but it is not known that it has a preventive or therapeutic effect on tumors.
【０００４】[0004]
【発明が解決しようとする課題】本発明の目的は、トレ
ハロースから構成される新規な免疫賦活剤を提供するこ
とにある。An object of the present invention is to provide a novel immunostimulant composed of trehalose.
【０００５】[0005]
【課題を解決するための手段】そこで本発明者らは、か
かる問題を解決するために鋭意研究した結果、トレハロ
ースがSarcoma180固形ガン細胞に対し、免疫賦活作用に
よる極めて高い抗腫瘍効果が存在することを見出し、本
発明を完成した。[Means for Solving the Problems] Therefore, as a result of intensive studies for solving the above problems, the present inventors have found that trehalose has an extremely high antitumor effect due to an immunostimulatory action on Sarcoma 180 solid cancer cells. And completed the present invention.
【０００６】すなわち、本発明は、トレハロースを有効
成分とする免疫賦活剤に関する。That is, the present invention relates to an immunostimulant containing trehalose as an active ingredient.
【０００７】更に本発明は、有効成分としてのトレハロ
ースとして、キノコ類から抽出されたトレハロースを含
む免疫賦活剤である。Further, the present invention is an immunostimulant containing trehalose extracted from mushrooms as trehalose as an active ingredient.
【０００８】本発明免疫賦活剤は、トレハロースを有効
成分として０．１％（ｗ／ｗ）以上含んでいる。The immunostimulant of the present invention contains trehalose as an active ingredient in an amount of 0.1% (w / w) or more.
【０００９】そして、本発明の免疫賦活剤は、食品又は
健康食品の形態にしたことを課題解消のための手段とす
る。The immunostimulant of the present invention is in the form of food or health food as a means for solving the problem.
【００１０】[0010]
【発明の実施の形態】次に、実施の形態により本発明を
具体的に説明するが、本発明はこれに限定されるもので
はない。BEST MODE FOR CARRYING OUT THE INVENTION Next, the present invention will be described in detail with reference to embodiments, but the present invention is not limited thereto.
【００１１】本発明に用いられるトレハロースは、酵
母、かび、キノコ、海草等の天然物中に広く分布する非
還元性の二糖類で、上記天然物から水又はエタノールな
どで熱抽出して得る方法や微生物の発酵による方法が知
られている。澱粉から微生物による醗酵法により調製さ
れた市販品としては、結晶性トレハロース粉末（商品名
『トレハ』、固形分当りのトレハロース含量９８％以
上、株式会社林原商事販売）及びトレハロース含有シロ
ップ（商品名『トレハスター』、固形分当りのトレハロ
ース含量２８％以上）、株式会社林原商事販売）があ
る。また、化学構造的には、Ｄ−グルコースの還元性基
どうしが結合したもので、その結合様式からα，α−ト
レハロース、α，β−トレハロース又はβ，β−トレハ
ロースの３種の異性体が存在するが、いずれも本発明に
使用することができる。これらのうち天然に存在する
α，α−トレハロースを使用するのが好ましい。The trehalose used in the present invention is a non-reducing disaccharide widely distributed in natural products such as yeast, fungi, mushrooms and seaweeds, and is obtained by heat extraction from the above natural products with water or ethanol. A method by fermentation of microorganisms and microorganisms is known. As commercially available products prepared from starch by a fermentation method using microorganisms, crystalline trehalose powder (trade name “treha”, trehalose content per solid content of 98% or more, sold by Hayashibara Shoji Co., Ltd.) and trehalose-containing syrup (trade name ““ Trehalaster ”, trehalose content per solid content of 28% or more), and Hayashibara Shoji Co., Ltd.). Further, in terms of chemical structure, reducing groups of D-glucose are bound to each other, and three types of isomers of α, α-trehalose, α, β-trehalose or β, β-trehalose are selected from the binding modes. Although present, any can be used in the present invention. Of these, it is preferable to use naturally occurring α, α-trehalose.
【００１２】上記本発明のトレハロースを有効成分とす
る免疫賦活剤は、これのみを含む製剤として単独で投与
してもよいが、医薬的に許容される医薬補助剤と組み合
わせた経口医薬組成物又は高カロリー輸液剤と併用して
用いるか、若しくは輸液製剤に添加して非経口組成物と
して使用することができる。また、保険機能食品、健康
食品などの医薬品以外の食品に添加する事もできる。The above-mentioned immunostimulant containing trehalose as an active ingredient of the present invention may be administered alone as a formulation containing only it, but an oral pharmaceutical composition or a pharmaceutically acceptable auxiliary agent in combination or It can be used in combination with a high-calorie infusion, or can be added to an infusion formulation and used as a parenteral composition. It can also be added to foods other than pharmaceuticals such as insurance functional foods and health foods.
【００１３】上記本発明のトレハロースを有効成分とす
る免疫賦活剤の投与剤型としては、各種の形態が治療目
的にに応じて選択でき、その代表的なものとして錠剤、
丸剤、顆粒剤、カプセル剤、散剤、シロップ剤等の経口
剤、座剤、液剤、懸濁剤、乳剤等の非経口剤が挙げられ
る。このような製剤は、薬理学的、製剤学的に許容され
る添加物を必要により添加し、公知の方法により製造す
ることができる。経口剤の製造に際しては、例えば通常
用いられる乳糖、白糖、澱粉、結晶セルロース、コーン
スターチ等の賦形剤、カルボキシメチルセルロース、寒
天、ゼラチン末等の崩壊剤、ポリビニルアルコール、メ
チルセルロース、ヒドロキシプロピルセルロース等の結
合剤、シリカ、ステアリン酸マグネシウム、タルク等の
滑沢剤、ヒドロキシプロピルメチルセルロース、白糖等
のコーティング剤等を使用すればよい。また、溶液剤、
懸濁剤、シロップ剤等の経口液剤、注射剤の製造に際し
ては、注射用蒸留水、生理食塩水等に溶解ないし、懸濁
し、例えば無機又は有機の酸あるいは塩基等のｐＨ調整
剤、等張化剤、安定化剤、希釈剤等を必要により添加す
ればよい。As the dosage form of the immunostimulant containing trehalose of the present invention as an active ingredient, various forms can be selected according to the purpose of treatment, and tablets are typical ones.
Examples thereof include oral agents such as pills, granules, capsules, powders and syrups, and parenteral agents such as suppositories, solutions, suspensions and emulsions. Such a preparation can be produced by a known method with the addition of pharmacologically and pharmaceutically acceptable additives as necessary. In the production of oral preparations, for example, commonly used excipients such as lactose, sucrose, starch, crystalline cellulose, corn starch, etc., disintegrating agents such as carboxymethyl cellulose, agar, gelatin powder, polyvinyl alcohol, methyl cellulose, hydroxypropyl cellulose, etc. A lubricant, a lubricant such as silica, magnesium stearate, talc, etc., a coating agent such as hydroxypropylmethylcellulose, sucrose, etc. may be used. Also, solution agents,
In the production of suspensions, oral liquids such as syrups, and injections, they are dissolved or suspended in distilled water for injection, physiological saline, etc., for example, pH adjusting agents such as inorganic or organic acids or bases, isotonic agents, etc. If necessary, an agent, a stabilizer, a diluent and the like may be added.
【００１４】本発明における免疫賦活剤は、イヌ、ネ
コ、ハムスターなどのペットや、牛，馬、豚、ニワトリ
等の家畜用の薬剤または飼料に添加して用いることがで
きる。The immunostimulant according to the present invention can be used by adding it to pets such as dogs, cats, hamsters, etc., or drugs or feeds for livestock such as cattle, horses, pigs and chickens.
【００１５】固形製剤として投与する場合にはトレハロ
ース濃度が０．１〜１００ｗ／ｗ％、輸液製剤として投
与する場合には０．１〜２０ｗ／ｗ％の範囲で適宜選択
できる。When administered as a solid preparation, the trehalose concentration can be appropriately selected within the range of 0.1 to 100 w / w%, and when administered as an infusion preparation, it can be appropriately selected within the range of 0.1 to 20 w / w%.
【００１６】本発明のトレハロースからなる免疫賦活剤
の投与量は、投与の方法、患者の年齢、体重、症状等に
より異なるが通常成人に対して経口投与の場合、１日当
たり１〜１０００ｍｇ／ｋｇ、好ましくは２５〜２５０
ｍｇ／ｋｇの範囲で適宜調節して投与することができ
る。The dose of the immunostimulant comprising trehalose of the present invention varies depending on the method of administration, the age, weight and symptoms of the patient, but when orally administered to an adult, it is usually 1 to 1000 mg / kg per day. Preferably 25-250
The dose can be appropriately adjusted and administered within the range of mg / kg.
【００１７】[0017]
【実施例１】［トレハロースの腹腔内投与によるSarcom
a180に対する抗腫瘍効果］５週齡のICR/Slc系雌性マウ
スを用い、1週間の予備飼育後、鼠径部皮下に継代維持
しているSarcoma180ガン細胞を約４×１０5移植した。
移植24時間後から連続10日間、トレハロースを生理食塩
水に懸濁した溶液（10mg/kg、25mg/kg、50mg/kg、100mg
/kg、250mg/kg）を腹腔内投与した。マウスは市販の固
形飼料（MF、オリエンタル酵母（株））および飲料水を
自由摂取させ、12時間のライトサイクル（8：00点灯、2
0：00消灯）で飼育した。移植1週間後から3週間後まで
の間、1週間に2回、生じた腫瘍の長径と短径をノギスを
用いて測定し、次の式に従って腫瘍サイズを求めた。
腫瘍サイズ(cm3) = 4/3πa2b/2、但し, a；短径(cm)
b；長径(cm)
さらに、腫瘍接種3週後に腫瘍を摘出し、腫瘍重量を測
定し、以下の式より腫瘍抑制率を算出した。
腫瘍抑制率(％) = (1-T/C)×100
但し, T；サンプル投与群のマウスの腫瘍サイズの平
均、n=7
C；生理食塩水投与群のマウスの腫瘍サイズの平均、n=7[Example 1] [Sarcom by intraperitoneal administration of trehalose
Antitumor effect against a180] Using a 5-week-old ICR / Slc strain female mouse, after preliminarily breeding for 1 week, about 4 × 10 5 Sarcoma 180 cancer cells subcultured subcutaneously in the groin were transplanted.
A solution of trehalose suspended in physiological saline 24 hours after transplantation for 10 consecutive days (10 mg / kg, 25 mg / kg, 50 mg / kg, 100 mg
/ kg, 250 mg / kg) was intraperitoneally administered. Mice were allowed free access to commercially available solid feed (MF, Oriental Yeast Co., Ltd.) and drinking water, and a 12-hour light cycle (lighting at 8:00, 2
It was bred at 00:00). From 1 week to 3 weeks after the transplantation, the major axis and minor axis of the resulting tumor were measured twice a week using a caliper, and the tumor size was determined according to the following formula. Tumor size (cm3) = 4 / 3πa2b / 2, but a; Minor axis (cm)
b; major axis (cm) Furthermore, the tumor was excised 3 weeks after the tumor inoculation, the tumor weight was measured, and the tumor suppression rate was calculated by the following formula. Tumor inhibition rate (%) = (1-T / C) × 100, T; mean tumor size of mice in sample administration group, n = 7 C; mean tumor size of mice in saline administration group, n = 7
【００１８】[0018]
【表１】
表１は、トレハロース10mg/kg〜250 mg/kgを腹腔内投与
した時の腫瘍サイズの経時変化を示すグラフである。[Table 1] Table 1 is a graph showing the change over time in tumor size when trehalose 10 mg / kg to 250 mg / kg was intraperitoneally administered.
【００１９】[0019]
【表２】
表２は、トレハロース10mg/kg〜250 mg/kgを腹腔内投与
した時の腫瘍重量ならびに腫瘍抑制率を示した表であ
る。[Table 2] Table 2 is a table showing the tumor weight and the tumor suppression rate when 10 mg / kg to 250 mg / kg of trehalose was intraperitoneally administered.
【００２０】表１に経時的な腫瘍サイズの変化を示し
た。また、表２に摘出した腫瘍の平均重量と腫瘍抑制率
を示した。50mg/kgで最大の抗腫瘍効果が認められ（抑
制率７６％）、その濃度をピークに、濃度が高くても低
くても抗腫瘍効果は低下した。従って、腹腔内投与によ
る抗腫瘍効果の最適濃度は50mg/kgであることがわか
る。Table 1 shows the change in tumor size over time. In addition, Table 2 shows the average weight of the extracted tumor and the tumor suppression rate. The maximum antitumor effect was observed at 50 mg / kg (suppression rate: 76%), and the antitumor effect was reduced at the peak concentration, regardless of whether the concentration was high or low. Therefore, it is found that the optimal concentration of antitumor effect by intraperitoneal administration is 50 mg / kg.
【００２１】[0021]
【実施例２】［トレハロースの経口投与によるSarcoma1
80に対する抗腫瘍効果］５週齡のICR/Slc系雌性マウス
を用い、1週間の予備飼育後、鼠径部皮下に継代維持し
ているSarcoma180ガン細胞を約４×１０5移植した。移
植24時間後から連続10日間、トレハロースを生理食塩水
に懸濁した溶液（10mg/kg、25mg/kg、50mg/kg、100mg/k
g、250mg/kg）を胃ゾンデを用いて経口投与した。マウ
スは市販の固形飼料（MF、オリエンタル酵母（株））お
よび飲料水を自由摂取させ、12時間のライトサイクル
（8：00点灯、20：00消灯）で飼育した。移植1週間後か
ら3週間後までの間、1週間に2回、生じた腫瘍の長径と
短径をノギスを用いて測定し、次の式に従って腫瘍サイ
ズを求めた。
腫瘍サイズ(cm3) = 4/3πa2b/2、但し, a；短径(cm)
b；長径(cm)
さらに、腫瘍接種3週後に腫瘍を摘出し、腫瘍重量を測
定し、以下の式より腫瘍抑制率を算出した。
腫瘍抑制率(％) = (1-T/C)×100
但し, T；サンプル投与群のマウスの腫瘍サイズの平
均、n=7
C；生理食塩水投与群のマウスの腫瘍サイズの平均、n=7[Example 2] [Sarcoma 1 by oral administration of trehalose
Antitumor effect against 80] Using 5 weeks old ICR / Slc strain female mice, after preliminarily breeding for 1 week, about 4 × 10 5 Sarcoma 180 cancer cells subcultured under subcutaneous in the groin were transplanted. A solution of trehalose suspended in physiological saline for 24 consecutive days after transplantation (10 mg / kg, 25 mg / kg, 50 mg / kg, 100 mg / k
g, 250 mg / kg) was orally administered using a gastric sonde. Mice were allowed to freely ingest a commercially available solid feed (MF, Oriental Yeast Co., Ltd.) and drinking water, and were bred under a 12-hour light cycle (lights on at 8:00, lights off at 2:00). From 1 week to 3 weeks after the transplantation, the major axis and minor axis of the resulting tumor were measured twice a week using a caliper, and the tumor size was determined according to the following formula. Tumor size (cm3) = 4 / 3πa 2 b / 2, where a; Minor axis (cm)
b; major axis (cm) Furthermore, the tumor was excised 3 weeks after the tumor inoculation, the tumor weight was measured, and the tumor suppression rate was calculated by the following formula. Tumor inhibition rate (%) = (1-T / C) × 100, T; mean tumor size of mice in sample administration group, n = 7 C; mean tumor size of mice in saline administration group, n = 7
【００２２】[0022]
【表３】
表３は、トレハロース10mg/kg〜250 mg/kgを経口投与し
た時の腫瘍サイズの経時変化を示すグラフである。[Table 3] Table 3 is a graph showing the change over time in tumor size when 10 mg / kg to 250 mg / kg of trehalose was orally administered.
【００２３】[0023]
【表４】
表４は、トレハロース10mg/kg〜250 mg/kgを経口投与し
た時の腫瘍重量ならびに腫瘍抑制率を示した表である。[Table 4] Table 4 is a table showing the tumor weight and the tumor suppression rate when trehalose 10 mg / kg to 250 mg / kg was orally administered.
【００２４】表３に経時的な腫瘍サイズの変化を示し
た。また、表４に摘出した腫瘍の平均重量と腫瘍抑制率
を示した。経口投与の場合は、腹腔内投与の場合と違っ
て、25〜250mg/kgの広範囲の濃度で抗腫瘍効果が認めら
れた。特に、100mg/kgで最大の腫瘍抑制率（73.1％）で
あり、他の濃度でも70％に近い抗腫瘍効果のあることが
わかる。Table 3 shows the change in tumor size over time. In addition, Table 4 shows the average weight of the extracted tumor and the tumor suppression rate. In the case of oral administration, unlike the case of intraperitoneal administration, an antitumor effect was observed in a wide range of concentrations of 25 to 250 mg / kg. In particular, the maximum tumor suppression rate (73.1%) was obtained at 100 mg / kg, and it was found that other concentrations have an antitumor effect close to 70%.
【００２５】[0025]
【発明の効果】本発明であるトレハロースを有効成分と
する免疫賦活剤は、Sarcoma180移植ガンに対し強い抗腫
瘍活性を持っており、新規なBRM として有用である。本
抗腫瘍活性は、免疫賦活効果（マクロファージの活性
化）によるものと考えられ、免疫活性低下による様々な
疾病に対しても有効である。また、食品の原料や甘味料
としても利用されているトレハロースは、従来の抗癌剤
等と比べ毒性がなく、安価で安全である。INDUSTRIAL APPLICABILITY The immunostimulant containing trehalose as an active ingredient of the present invention has a strong antitumor activity against Sarcoma 180 transplanted cancer and is useful as a novel BRM. This antitumor activity is considered to be due to an immunostimulatory effect (macrophage activation), and is also effective against various diseases caused by reduced immune activity. In addition, trehalose, which is also used as a raw material for foods and as a sweetener, is less toxic than conventional anticancer agents and is inexpensive and safe.
───────────────────────────────────────────────────── フロントページの続き Ｆターム(参考） 4C057 BB01 BB03 4C086 AA01 AA02 EA01 MA01 MA04 NA06 NA07 NA14 ZB09 ZB26 4C088 AA02 AC17 BA12 NA06 NA07 NA14 ZB09 ZB26 ─────────────────────────────────────────────────── ─── Continued front page F-term (reference) 4C057 BB01 BB03 4C086 AA01 AA02 EA01 MA01 MA04 NA06 NA07 NA14 ZB09 ZB26 4C088 AA02 AC17 BA12 NA06 NA07 NA14 ZB09 ZB26
Claims (4)
を特徴とする免疫賦活剤。1. An immunostimulant comprising trehalose as an active ingredient.
て、キノコ類から抽出されたトレハロースを含む請求項
１記載の免疫賦活剤。2. The immunostimulant according to claim 1, which contains trehalose extracted from mushrooms as trehalose as the active ingredient.
１％（ｗ／ｗ）以上含んでなる請求項１又は２記載の免
疫賦活剤。3. The trehalose as an active ingredient is used as an active ingredient.
The immunostimulant according to claim 1 or 2, which comprises 1% (w / w) or more.
形態にある請求項１乃至３いずれかに記載の免疫賦活
剤。4. The immunostimulant according to claim 1, which is in the form of food or health food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001269859A JP2003081839A (en) | 2001-09-06 | 2001-09-06 | Immunopotentiator including trehalose |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001269859A JP2003081839A (en) | 2001-09-06 | 2001-09-06 | Immunopotentiator including trehalose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2003081839A true JP2003081839A (en) | 2003-03-19 |
Family
ID=19095600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001269859A Pending JP2003081839A (en) | 2001-09-06 | 2001-09-06 | Immunopotentiator including trehalose |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2003081839A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9127322B2 (en) | 2007-12-10 | 2015-09-08 | Oriental Yeast Co., Ltd. | Yeast having immunopotentiating capability and food or feed |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1160490A (en) * | 1997-08-19 | 1999-03-02 | Hayashibara Biochem Lab Inc | Liver function-regulating medicine |
| JP2000007570A (en) * | 1998-06-24 | 2000-01-11 | Hayashibara Biochem Lab Inc | Anti-endocrinosis agent |
| WO2002038146A1 (en) * | 2000-11-07 | 2002-05-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Mucosal immunomodulator and use thereof |
-
2001
- 2001-09-06 JP JP2001269859A patent/JP2003081839A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1160490A (en) * | 1997-08-19 | 1999-03-02 | Hayashibara Biochem Lab Inc | Liver function-regulating medicine |
| JP2000007570A (en) * | 1998-06-24 | 2000-01-11 | Hayashibara Biochem Lab Inc | Anti-endocrinosis agent |
| WO2002038146A1 (en) * | 2000-11-07 | 2002-05-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Mucosal immunomodulator and use thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9127322B2 (en) | 2007-12-10 | 2015-09-08 | Oriental Yeast Co., Ltd. | Yeast having immunopotentiating capability and food or feed |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5320849A (en) | Anti-virus agent | |
| EP1429789B1 (en) | Anti-infectious carbohydrates | |
| JPWO2012141018A1 (en) | Composition, sugar metabolism improving agent, and method for improving sugar metabolism | |
| US20170239282A1 (en) | Bidens pilosa and polyacetylenic compounds for prevention and treatment of coccidiosis | |
| CN1833644A (en) | Abrotine, its derivative dihydro-abrotine, artemether, arteether and arte sunate in use of pharmacy | |
| JPH08503699A (en) | Pyrimidine nucleotide precursors for the treatment of systemic inflammation and inflammatory hepatitis | |
| JP2018002604A (en) | Natural killer cell activators | |
| JP2003081839A (en) | Immunopotentiator including trehalose | |
| KR101905863B1 (en) | Pharmaceutical Composition for Preventing or Treating of Inflammatory Diseases and Metabolic Diseases Comprising hyaluronic acid Nanoparticles | |
| JP4484267B2 (en) | Cancer immunostimulant and allergy immunosuppressant | |
| CN110327355B (en) | Combination product comprising a limonoid and an SGLT-2 inhibitor | |
| KR102063398B1 (en) | Compositions for preventing or treating kidney cancer comprising PFI-3 | |
| CH646059A5 (en) | ANTIBIOTIC COMPOSITIONS CONTAINING A MACROLIDE AND AN AMINOHETEROSIDE. | |
| CN109846876B (en) | Application of lignan compound in resisting tumor and preparation of medicine thereof | |
| JPH08157377A (en) | Preventing and therapeutic agent for diarrhea of livestock or the like | |
| JPH11302191A (en) | Immunoactivator and antitumor agent containing extract from lyophyllum decastes (fr.) sing. as active ingredient | |
| JPS62265223A (en) | Avermectin as growth promotor | |
| CN109464435B (en) | Pharmaceutical composition for preventing and treating fish liver inflammation | |
| JPWO2007074727A1 (en) | Oral candidiasis treatment | |
| CN104968357B (en) | Bidens bipinnata and polyacetylene compounds for preventing and treating coccidiosis | |
| CN108938653B (en) | Application of oxidized 1, 4-beta-D-glucuronic acid oligosaccharide in preparation of medicine for treating Alzheimer disease | |
| JP4825957B2 (en) | Antitumor agent | |
| JP2579486B2 (en) | Central nervous system depressant | |
| CN1162155C (en) | Application of phenazinone derivative in preparing antineoplastic and tumor transfer-resistant medicines | |
| CN114225043A (en) | Application of stachyose modified substance in preparation of medicine for treating castration-resistant prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080207 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080207 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080207 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110607 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111025 |